Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the ...
Nasal Polyps Treatment Market Set To Surge To $4.24 Billion By 2030 At A 5.6% CAGR
Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...
Pulmonology Advisor4d
Silent Rhinovirus Infection Prevalent in Nasal Tissues
Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...
Clinical Advisor4d
FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
The Manila Times5d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...